论文信息 - Editorial: infliximab or adalimumab as first‐ or second‐line anti‐TNF—conflicting evidence—authors' reply - 字舞流文

Editorial: infliximab or adalimumab as first‐ or second‐line anti‐TNF—conflicting evidence—authors' reply

J. Ludvigsson | J. Halfvarson | O. Grip | H. Hjortswang | P. Karling | S. Montgomery | O. Olén | P. Myrelid | A. Gustavsson | Yang Cao | C. Eriksson | I. Visuri | E. Mårdberg | Isabella Visuri